Therapeutic approach to home treatment of deep venous thrombosis in the elderly;Tratamiento de la trombosis venosa profunda en pacientes mayores de 60 años en una unidad de hospitalización a domicilio

Revista Espanola de Geriatria y Gerontologia

Volumn 37, Issue 5, 2002, Pages 254-259

  Alvarez Nebreda M L ^a   Perez Tamayo I ^a   Branas Baztan F ^a   Rada Martinez S ^a   Serra Rexach, J A ^a   Gonzalez Ramallo V ^a   Granda Martin M J ^a   Ortiz Alonso, J ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Deep vein thrombosis; Elderly population; Home treatment; Low molecular weight heparin; Out patient treatment

Indexed keywords

COUMARIN ANTICOAGULANT; LOW MOLECULAR WEIGHT HEPARIN;

AGED; ARTICLE; BLEEDING; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOPPLER ECHOGRAPHY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HOME CARE; HOSPITAL ADMISSION; HUMAN; INTERMETHOD COMPARISON; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; PHLEBOGRAPHY; RISK FACTOR;

EID: 0038355064     PISSN: 0211139X     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0211-139x(02)74819-1     Document Type: Article

References (37)

1. Nordstrom M, Lindblad B, Bergquist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992;232:155-60.
2. Boccalon H, Elias A, Chale JJ, Cadene A, Gabriel S. Clinical outcome and cost of hospital vs home treatment of proximal deep vein trombosis with a low-molecular-weight heparin. The Vascular Midi-Pyrenees Study. Arch Intern Med 2000;160:1769-73.
3. Brandjes DP, Heijboer H, Büller HR, de Rijk M, Jagt M, ten Cate Jw. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992;327:1485-9.
4. Hull RD, Raskob GE, Rosenbloom D, Panju AA, Brill-Edwards P, Ginsberg JS, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990;322:1260-4.
5. Gallus A, Jackaman J, Tillet J, Mills W, Wycherley A. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986;2:1293-6.
6. Hull RD, Raskob GE, Hirsh J, et al. Continous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315:1109-14.
7. Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991;324:1865-75.
8. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-82.
9. Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins: a meta-analysis. Arch Intern Med 1995;155:601-7.
10. Prandoni P, Lensing AWA, Boller HR, Carta M, Cogo A, Vigo M, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441-5.
11. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992;79:1-17.
12. Frydman AM, Bara L, Le Roux Y, Woler M, Chauliac F, Samama MM. The antithrombotic activity and pharmacokinetics of enoxaparin, a low-molecular-weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol 1988;28:609-18.
13. Koopman MW, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, et al. The TASMAN Study Group. Treatment of venous trombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weigth heparin administered at home. N Engl J Med 1996;334:682-7.
14. Levine M, Gent M, Hirsh J, Lederc J, Anderson D, Weitz J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-81.
15. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119:176S-93S.
16. Dunn AS, Schechter C, Gotlin A, Vomvolakis D, Jacobs E, Sacks Hs, et al. Outpatient treatment of deep venous thrombosis in diverse inner-city patients. Am J Med 2001;110:458-62.
17. Grau E, Tenias JM, Real E, Medrano J, Ferrer R, Pastor E, et al. Home treatment of deep venous trombosis with low-molecular-weight heparin: long-term incidence of recurrent venous thromboembolism. Am J Hematol 2001;67:10-14.
18. Tillman DJ, Charland SL, Witt DM. Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization. Arch Intern Med 2000;160:2926-32.
19. O'Brien B, Levine MD, Willan A, Goeree R, Haley S, Blackhouse G, et al. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. Arch Intern Med 1999;159:2298-304.
20. Grau E, Real E, Pastor E, Viciano V, Aquilo J. Home treatment of deep vein trombosis: a two years experience of a single institution. Haematologica 1998;83:438-41.
21. Van den Belt GM, Bossuyt PMM, Prins MH, Gallus AS, Buller HR. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis-An economic evaluation. Thromb Haemost 1998;79:259-63.
22. Harrison J, McGinnis J, Crowther M, Ginsberg J, Hirsh J. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med 1998;158:2001-3.
23. Wells PS, Kovacs MJ, Bormanis J, Forqie MA, Goudie D, Morrow B, et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weigth heparin. Arch Intern Med 1998;158:1809-12.
24. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657-62.
25. Belcaro G, Nicolaides AN, Cesarone MR, Laurora G, De Sanctis MT, Incandela L, et al. Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis. Angiology 1999;50:781-7.
26. Katz S, Stroud MV. Functional assessment in geriatrics. A review of progress and directions. J Am Geriatr Soc 1989;37:267-71.
27. Verstraete M. Pharmacotherapeutic aspects of unfractionated and low-molecular-weight heparin. Drugs 1990;40:498-530.
28. Aiach M. A new low-molecular-weigth heparin derivative, in vitro and in vivo studies. Thromb Res 1983;31:611-21.
29. Cade JF, Buchanon MR, Boneu B, et al. A comparison of the antithrombotic and hemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb Res 1984;35:613-25.
30. Carter CJ, Kelton JG, Hirsh J, Gent M. Relationship between the antithrombotic and anticoagulant effects of low molecular weight heparin. Thromb Res 1981;21:169-74.
31. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acuta pulmonary embolism. N Engl J Med 1997;337:663-9.
32. Hull Rd, Raskob GE, Brandt RF, Pineo GF, Elliott G, Stein PD, et al. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. Arch Intern Med 2000;160:229-36.
33. Lagerstedt CI, Olsson CG, Fagher BO, Oquist B, Albrechtsson U. Need for long term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985;2:515-8.
34. Schulman S, Granqvist S, Holmstrom M, Carlsson A, Lindfmartxer P, Nicol P, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997;336:393-8.
35. Eikelboom J, Baker R. Routine home treatment of deep vein thrombosis. BMJ 2001;322:1192-3.
36. Vinson DR. Eligibility criteria for home treatment of deep vein thrombosis vary. BMJ 2001;323:866.
37. Schwarz T, Schmidt B, Höhlein U, Beyer J, Schroder HE, Schellong SM. Eligibility for home treatment of deep vein thrombosis: prospective study. BMJ 2001;322:1212-3.